Aggressive tumor behavior is usually manifested by increased proliferation, and is most likely associated with """"""""activation"""""""" of tumor cells by a number of oncogenes and growth factors. The general goals of this research proposal are to identify markers of tumor proliferation and to investigate their association with clinical outcome in patients with node-negative breast cancer. Specifically, we propose: [1] To investigate the abilities of antibodies against the four proliferation-associated antigens, Ki67, PCNA/cyclin, topoisomerase II, and histone H3, to measure cell-cycle kinetics by immunohistochemistry (IHC) by comparing IHC results to existing flow cytometric S-phase results in a feasibility study of 200 breast carcinomas. [2] To definitively evaluate the prognostic significance of selected proliferation and activation markers using comprehensive """"""""training"""""""" and """"""""validation"""""""" datasets from over 600 node-negative breast carcinomas. The first anticipated benefit of the proposed studies is the validation of IHC methods to measure tumor proliferation rate. IHC technology possesses several technical and economic advantages which would allow the prognostic evaluation of tumor cell-cell kinetics on a much larger scale than is now possible with current techniques (e.g. flow cytometry). Success in these endeavors will provide clinicians with data regarding proliferation and activation markers that they can apply in making treatment decisions.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Park, Jun Hyoung; Vithayathil, Sajna; Kumar, Santosh et al. (2016) Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14:2154-2165
Pathiraja, Thushangi N; Nayak, Shweta R; Xi, Yuanxin et al. (2014) Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med 6:229ra41
Zhang, Yi; Tseng, Chun-Chih; Tsai, Yuan-Li et al. (2013) Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One 8:e80071
Machado, Heather L; Kittrell, Frances S; Edwards, David et al. (2013) Separation by cell size enriches for mammary stem cell repopulation activity. Stem Cells Transl Med 2:199-203
Zhang, Xiaomei; Claerhout, Sofie; Prat, Aleix et al. (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73:4885-97
Boone, David N; Lee, Adrian V (2012) Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog 17:161-73
Casa, Angelo J; Potter, Adam S; Malik, Simeen et al. (2012) Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat 132:61-73
Creighton, Chad J (2012) Molecular classification and drug response prediction in cancer. Curr Drug Targets 13:1488-94
Pathiraja, Thushangi N; Shetty, Priya B; Jelinek, Jaroslav et al. (2011) Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res 17:4177-86
Heckman-Stoddard, B M; Vargo-Gogola, T; Herrick, M P et al. (2011) P190A RhoGAP is required for mammary gland development. Dev Biol 360:1-10

Showing the most recent 10 out of 260 publications